Gefitinib in heavily pretreated non small cell lung cancer: Results of the expanded access program in Eastern France.

被引：0
|
作者：
Spaeth, D
Deplanque, G
Favrot, N
Paillot, N
Lang, MP
Cuguiliere, A
Seigneur, J
机构：
[1] Ctr Alexis Vautrin, Nancy, France
[2] Dept Oncol, Scy Chazelles, France
[3] Ctr GF Leclerc, Dijon, France
[4] Serv Pneumol, Metz, France
[5] Serv Pneumol, Mt St Martin, France
[6] HIA Legouest, Metz, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7323
引用
收藏
页码：696S / 696S
页数：1
相关论文
共 50 条
  • [21] Lessons from the ‘Iressa’ Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations
    R Stahel
    A Rossi
    L Petruzelka
    P Kosimidis
    F de Braud
    M M Bernardo
    P-J Souquet
    H Soto Parra
    C Gridelli
    British Journal of Cancer, 2003, 89 : S19 - S23
  • [22] Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): The expanded access protocol experience at the University of Pennsylvania
    Veronese, ML
    Algazy, K
    Bearn, L
    Eaby, B
    Alavi, J
    Evans, T
    Stevenson, JP
    Shults, J
    CANCER INVESTIGATION, 2005, 23 (04) : 296 - 302
  • [23] Real-World Results in Non-Squamous Non-Small Cell Lung Cancer Patients: Italian Nivolumab Expanded Access Program
    Grossi, F.
    Crino, L.
    Delmonte, A.
    Turci, D.
    Signorelli, D.
    De Marinis, F.
    Parra, H. Soto
    Galetta, D.
    Cappuzzo, F.
    Sperandi, F.
    Tiseo, M.
    Puppo, G.
    Roila, F.
    Migliorino, M. R.
    Tonini, G.
    Cognetti, F.
    Santoro, A.
    Tassinari, D.
    Scoppola, A.
    Giannarelli, D.
    Cortesi, E.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1841 - S1841
  • [24] Local Experience in an Expanded Access Program of Nivolumab in Advanced Non-Small Cell Lung Cancer in Brazil
    Araujo, Luiz H.
    Baldotto, Clarissa
    Martins, Cicero
    Zukin, Mauro
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1303 - S1303
  • [25] Gefitinib in non-small cell lung cancer
    Tamura, K
    Fukuoka, M
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 985 - 993
  • [26] Gefitinib (ZD 1839, Iressa®) in treatment of advanced non-small cell lung cancers -: one institutional experience on an expanded access program
    Zemanova, M
    Petruzelka, L
    Honova, H
    Dvorak, J
    Tomancova, V
    Safanda, M
    Mares, P
    LUNG CANCER, 2005, 49 : S377 - S377
  • [27] Compassionate use experience with gefitinib in poor performance (PS) patients with advanced non-small-cell lung cancer (NSCLC) treated in an expanded access program (EAP).
    Zinner, R
    Govindan, R
    Wozniak, AJ
    Wade, JL
    Belani, CP
    Thienelt, CD
    Hensing, TA
    Reiling, RB
    Natale, RB
    Wiznitzer, I
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 636S - 636S
  • [28] Gefitinib ('Iressa', ZD1839) given in the 'Iressa' Expanded Access Programme in patients with non-small-cell lung cancer
    Chioni, A
    Barbieri, F
    Baldini, E
    Orlandini, C
    Ricci, S
    Conte, PF
    BRITISH JOURNAL OF CANCER, 2003, 89 : S26 - S27
  • [29] ZD1839 for the treatment of heavily pretreated non-small cell lung cancer.
    Wu, YL
    Yang, X
    Yang, JJ
    Huang, YJ
    Chen, G
    Gu, LJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 701S - 701S
  • [30] BEVACIZUMAB AS A SALVAGE TREATMENT IN HEAVILY PRETREATED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS
    Hadoux, J.
    Angelergues, A.
    Bidault, F.
    Soria, J.
    Planchard, D.
    Le Chevalier, T.
    Massard, C.
    Besse, B.
    ANNALS OF ONCOLOGY, 2010, 21 : 151 - 151
12345